Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety, absorption, and elimination study of RO7795068 in obesity research
NL-OMON58888Phase 1Completed
- Sponsor
- Roche
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of zilebesiran in obesity, sponsored by Roche. Started Mar 2026; status: completed.
02
Drugs
zilebesiran
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON58888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58888.